Lupin Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Lupin heeft een totaal eigen vermogen van ₹157.2B en een totale schuld van ₹31.7B, wat de schuld-eigenvermogensverhouding op 20.2% brengt. De totale activa en totale passiva bedragen respectievelijk ₹254.8B en ₹97.6B. De EBIT Lupin is ₹37.3B waardoor de rentedekking 21.1 is. Het heeft contanten en kortetermijnbeleggingen van ₹29.1B.

Belangrijke informatie

20.2%

Verhouding schuld/eigen vermogen

₹31.72b

Schuld

Rente dekkingsratio	21.1x
Contant	₹29.12b
Aandelen	₹157.20b
Totaal verplichtingen	₹97.62b
Totaal activa	₹254.82b

Recente financiële gezondheidsupdates

Recent updates

Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 10

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Sep 17

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Aug 01

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Jul 12

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

May 08

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Apr 20

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹150.2B ) LUPIN } overtreffen de korte termijn passiva ( ₹79.9B ).

Langlopende schulden: De kortetermijnactiva LUPIN ( ₹150.2B ) overtreffen de langetermijnschulden ( ₹17.7B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 1.7% ) LUPIN wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van LUPIN is de afgelopen 5 jaar gedaald van 63.4% naar 20.2%.

Schuldendekking: De schuld van LUPIN wordt goed gedekt door de operationele kasstroom ( 98.2% ).

Rentedekking: De rentebetalingen op de schuld van LUPIN worden goed gedekt door EBIT ( 21.1 x dekking).

Lupin Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Recent updates

Price target increased by 7.3% to ₹2,211

Price target increased by 7.0% to ₹2,191

Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2025 Results on Nov 07, 2024

Lupin Limited Announces its Wholly Owned Subsidiary Lupin Management, Inc., USA Appoints Claus Jepsen as President, Global Specialty

Lupin Launches First Generic of Pred Forte® in the United States

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Price target increased by 12% to ₹1,835

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited Approves Dividend for Year Ended March 31, 2024

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Full year 2024 earnings: EPS misses analyst expectations

Dividend increased to ₹8.00

Lupin Limited, Annual General Meeting, Aug 02, 2024

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets